Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 3Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 4Neoplasm Metastasis 1

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × AZD 6244 × Tumor-Agnostic × Clear all
NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

AstraZeneca

Phase 1 Active not recruiting
58 enrolled
Tumor-Agnostic

Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

AstraZeneca

Phase 1 Completed
48 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

AstraZeneca

Phase 1 Completed
21 enrolled 4 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡